Stock listing
Pharma Equity Group A/s Class A
Selected listing: PEG · OMXCOP · DKK · DK
Pharma Equity Group A/s Class A (Copenhagen:PEG), Health Technology. Latest release Sep 7, 2026: Pharma Equity Group A/S – Challenge to Arbitral Award.

- Ticker
- Copenhagen:PEG
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- Copenhagen
- Currency
- DKK
About Pharma Equity Group A/s Class A
The company focuses on the pharmaceutical sector, engaging in activities related to equity investments. As a publicly traded entity, it operates under the regulations of the Danish market.
Latest news from Pharma Equity Group A/s Class A
Pharma Equity Group A/S – Challenge to Arbitral Award
September 7, 2026
Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant
May 11, 2026
Proceedings of the Annual General Meeting of Pharma Equity Group A/S
April 17, 2026
Notice convening the annual general meeting in Pharma Equity Group A/S
March 25, 2026
Pharma Equity Group A/S - Annual Report 2025
March 25, 2026
Research Pharma Equity Group A/s Class A
Pharma Equity Group A/s Class A company profile
View the public company page for Pharma Equity Group A/s Class A on 6ix.
Pharma Equity Group A/s Class A news
Read company news and market updates connected to Pharma Equity Group A/s Class A.
Pharma Equity Group A/s Class A investor events
Find investor webinars, events, and replay context for Pharma Equity Group A/s Class A.
Alternate listings
PEGC:AQUISUK
GB · DKK
Alternate listing for Pharma Equity Group A/s Class A; the primary context on this page is PEG:OMXCOP.
PEGC:AQUISEU
GB · DKK
Alternate listing for Pharma Equity Group A/s Class A; the primary context on this page is PEG:OMXCOP.
0REU:LSE
GB · DKK
Alternate listing for Pharma Equity Group A/s Class A; the primary context on this page is PEG:OMXCOP.
PEGC:TURQUOISE
GB · DKK
Alternate listing for Pharma Equity Group A/s Class A; the primary context on this page is PEG:OMXCOP.